KB-141
KB-141 is a synthetic thyroid hormone receptor beta-selective agonist studied preclinically for obesity and dyslipidaemia. In primates it lowered cholesterol and increased metabolic rate with a wide margin over cardiac effects, but it never advanced to substantial human trials.
01 Overview
KB-141 was developed as a TR-beta-selective thyromimetic to exploit thyroid hormone's metabolic benefits while avoiding cardiac toxicity. Studies in rodents and non-human primates demonstrated cholesterol lowering, weight loss and increased energy expenditure at doses well below those affecting heart rate.
Human development did not progress far, so real-world efficacy and safety in people are essentially unknown. It appears in the metabolic grey market on the strength of its animal data rather than clinical evidence.
02 Mechanism
Selective thyroid hormone receptor beta agonist that activates hepatic and metabolic gene programmes, lowering cholesterol and raising metabolic rate with limited cardiac TR-alpha engagement.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Unvalidated | 1 mg/day | Oral | No human protocol exists; illustrative only |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Cholesterol loweringReduced cholesterol in rodent and primate studies. | Preclinical | ||
| Increased metabolic rateRaised energy expenditure and weight loss in animals. | Preclinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Thyroid axis suppressionExpected pituitary TSH suppression from thyromimetic action. | Moderate | Expected | Preclinical | |
| Unknown human safetyNo meaningful human safety data. | Moderate | Uncharacterised | Unconfirmed |